GTx, Inc. Share Price Nasdaq
Equities
US40052B1089
Biotechnology & Medical Research
Sales 2024 * | 878K 73.12M | Sales 2025 * | 675K 56.2M | Capitalization | 25.63M 2.13B |
---|---|---|---|---|---|
Net income 2024 * | -35M -2.91B | Net income 2025 * | -48M -4B | EV / Sales 2024 * | 29.2 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 38 x |
P/E ratio 2024 * |
-0.72
x | P/E ratio 2025 * |
-1.03
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.7% |
Latest transcript on GTx, Inc.
Managers | Title | Age | Since |
---|---|---|---|
James Breitmeyer
FOU | Founder | 70 | 01/97/01 |
Richard Vincent
DFI | Director of Finance/CFO | 61 | 01/17/01 |
Salim Yazji
CTO | Chief Tech/Sci/R&D Officer | 55 | 17/21/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Hale
FOU | Founder | 75 | 01/97/01 |
Dan Kisner
BRD | Director/Board Member | 77 | 07/19/07 |
Rosemary Mazanet
BRD | Director/Board Member | 67 | 27/21/27 |
1st Jan change | Capi. | |
---|---|---|
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |